JP2024532735A5 - - Google Patents

Info

Publication number
JP2024532735A5
JP2024532735A5 JP2024507885A JP2024507885A JP2024532735A5 JP 2024532735 A5 JP2024532735 A5 JP 2024532735A5 JP 2024507885 A JP2024507885 A JP 2024507885A JP 2024507885 A JP2024507885 A JP 2024507885A JP 2024532735 A5 JP2024532735 A5 JP 2024532735A5
Authority
JP
Japan
Prior art keywords
cancer
fluoro
compound according
methoxy
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024507885A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024532735A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/039968 external-priority patent/WO2023018809A1/en
Publication of JP2024532735A publication Critical patent/JP2024532735A/ja
Publication of JP2024532735A5 publication Critical patent/JP2024532735A5/ja
Pending legal-status Critical Current

Links

JP2024507885A 2021-08-10 2022-08-10 複素環式化合物及び使用方法 Pending JP2024532735A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163231543P 2021-08-10 2021-08-10
US63/231,543 2021-08-10
US202163289576P 2021-12-14 2021-12-14
US63/289,576 2021-12-14
PCT/US2022/039968 WO2023018809A1 (en) 2021-08-10 2022-08-10 Heterocyclic compounds and methods of use

Publications (2)

Publication Number Publication Date
JP2024532735A JP2024532735A (ja) 2024-09-10
JP2024532735A5 true JP2024532735A5 (https=) 2025-08-19

Family

ID=85201031

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024507885A Pending JP2024532735A (ja) 2021-08-10 2022-08-10 複素環式化合物及び使用方法

Country Status (8)

Country Link
US (1) US20250122222A1 (https=)
EP (1) EP4384159A4 (https=)
JP (1) JP2024532735A (https=)
AU (1) AU2022328206A1 (https=)
CA (1) CA3228579A1 (https=)
MX (1) MX2024001894A (https=)
TW (1) TW202321242A (https=)
WO (1) WO2023018809A1 (https=)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019195609A2 (en) 2018-04-04 2019-10-10 Arvinas Operations, Inc. Modulators of proteolysis and associated methods of use
EP4067343A4 (en) 2019-11-29 2024-01-03 Taiho Pharmaceutical Co., Ltd. NEW PHENOLIC COMPOUND OR SALT THEREOF
UY39906A (es) * 2021-08-18 2023-03-31 Jacobio Pharmaceuticals Co Ltd Derivados de 1,4-oxazepano y usos de los mismos
EP4436571A4 (en) * 2021-11-24 2025-10-15 Merck Sharp & Dohme Llc SMALL MOLECULE INHIBITORS OF KRAS MUTATIONAL PROTEINS
JP2025510572A (ja) 2022-03-08 2025-04-15 レボリューション メディシンズ インコーポレイテッド 免疫不応性肺癌を治療するための方法
CA3247639A1 (en) 2022-05-06 2023-11-09 PAQ Therapeutics Inc. CHIMERAS TARGET KRAS-G12D PROTEOLYSIS
WO2023213269A1 (en) * 2022-05-06 2023-11-09 Zai Lab (Shanghai) Co., Ltd. Amide-substituted heterocyclic compounds as kras g12d modulators and uses thereof
CR20240508A (es) 2022-05-19 2024-12-20 Genentech Inc Compuestos aza-tetracíclicos de oxazepina y usos de los mismos
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2024008068A1 (en) * 2022-07-04 2024-01-11 Jacobio Pharmaceuticals Co., Ltd. K-ras mutant protein inhibitors
WO2024012519A1 (zh) * 2022-07-13 2024-01-18 北京华森英诺生物科技有限公司 Pan-kras抑制剂
TW202430179A (zh) 2022-11-21 2024-08-01 美商樹線生物科學公司 螺環二氫哌喃并嘧啶ＫＲａｓ抑制劑
WO2024119277A1 (en) * 2022-12-08 2024-06-13 Risen (Suzhou) Pharma Tech Co., Ltd. Kras inhibitors and pharmaceutical uses thereof
US12448399B2 (en) 2023-01-26 2025-10-21 Arvinas Operations, Inc. Cereblon-based KRAS degrading PROTACs and uses related thereto
AU2024241633A1 (en) 2023-03-30 2025-11-06 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
CR20250420A (es) 2023-04-07 2025-11-20 Revolution Medicines Inc Inhibidores macrocíclicos de ras
AR132338A1 (es) 2023-04-07 2025-06-18 Revolution Medicines Inc Inhibidores de ras
CN121464140A (zh) 2023-04-14 2026-02-03 锐新医药公司 Ras抑制剂的结晶形式、含有其的组合物及其使用方法
CN121100123A (zh) 2023-04-14 2025-12-09 锐新医药公司 Ras抑制剂的结晶形式
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
WO2025016899A1 (en) 2023-07-19 2025-01-23 Bayer Aktiengesellschaft Spirocyclic compounds for the treatment of cancer
WO2025026903A1 (en) 2023-07-31 2025-02-06 Bayer Aktiengesellschaft Imidazo pyrimidine compounds for the treatment of cancer
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025038936A1 (en) 2023-08-17 2025-02-20 Treeline Biosciences, Inc. Spirocyclic dihydropyranopyrimidine kras inhibitors
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
TW202528314A (zh) 2023-09-20 2025-07-16 美商亞特羅姆醫療公司 Ｋｒａｓ調節劑
TW202528315A (zh) 2023-09-21 2025-07-16 美商樹線生物科學公司 螺環二氫哌喃并吡啶ＫＲａｓ抑制劑
CN121941690A (zh) 2023-10-03 2026-04-28 Paq医疗公司 Kras蛋白水解靶向嵌合体
TW202529804A (zh) 2023-10-06 2025-08-01 美商安進公司 用於癌症治療的組合療法
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
AU2024361909A1 (en) 2023-10-20 2026-03-26 Merck Sharp & Dohme Llc Small molecule inhibitors of kras proteins
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025235740A1 (en) * 2024-05-08 2025-11-13 Merck Sharp & Dohme Llc Small molecule inhibitors of kras proteins
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025245127A1 (en) 2024-05-21 2025-11-27 Treeline Biosciences, Inc. Spirocyclic dihydropyranopyrimidine kras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026035945A1 (en) 2024-08-07 2026-02-12 Tesseract Medicines Us, Llc Covalent-induced drug conjugates targeting kras and comprising a topoisomerase payload
WO2026035947A1 (en) 2024-08-07 2026-02-12 Tesseract Medicines Us, Llc Kras-targeting covalent-induced drug conjugates comprising a topoisomerase payload
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026064520A1 (en) 2024-09-19 2026-03-26 Tesseract Medicines Us, Llc Covalent-induced drug conjugates targeting kras and comprising a tubulin inhibitor payload
WO2026064527A1 (en) 2024-09-19 2026-03-26 Tesseract Medicines Us, Llc Kras-targeting covalent-induced drug conjugates comprising a tubulin inhibitor payload
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103588792B (zh) * 2013-03-04 2016-03-23 中国科学院上海药物研究所 吡啶并嘧啶或嘧啶并嘧啶类化合物、其制备方法、药物组合物及其用途
EP3908283A4 (en) * 2019-01-10 2022-10-12 Mirati Therapeutics, Inc. KRAS G12C INHIBITORS
MX2022002465A (es) * 2019-08-29 2022-05-19 Mirati Therapeutics Inc Inhibidores de kras g12d.
JP2023553492A (ja) * 2020-12-15 2023-12-21 ミラティ セラピューティクス， インコーポレイテッド アザキナゾリン汎ＫＲａｓ阻害剤

Similar Documents

Publication Publication Date Title
JP2024532735A5 (https=)
JP2025508703A5 (https=)
JP2024532733A5 (https=)
JP2024517695A5 (https=)
JP2025508702A5 (https=)
KR102304108B1 (ko) 림프종 치료를 위한 치환된 2,3-디히드로이미다조[1,2-c]퀴나졸린의 용도
US10308629B2 (en) 1H-pyrrol-3-amines
CN113474337A (zh) 作为fgfr抑制剂用于治疗癌症的7-((3，5-二甲氧基苯基)氨基)喹喔啉衍生物
CN113490666A (zh) 作为fgfr酪氨酸激酶的抑制剂的取代的吡唑并[1,5-a]吡啶化合物
US10786492B2 (en) Formylated N-heterocyclic derivatives as FGFR4 inhibitors
AU2021257373B2 (en) Pyridopyrimidinone derivatives and their use as Aryl hydrocarbon receptor modulators
WO2016040848A1 (en) Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
WO2016203404A1 (en) Compounds and compositions for inhibiting the activity of shp2
WO2015157128A1 (en) Therapuetic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity
WO2016142312A1 (en) Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations
KR20180013850A (ko) 치환된 2,3-디히드로이미다조[1,2-c]퀴나졸린의 용도
EP3390401A1 (en) Hetero-1,5,6,7-tetrahydro-4h-indol-4-ones
JP7280286B2 (ja) びまん性大細胞型ｂ細胞リンパ腫を治療するための５－フルオロ－４－（４－フルオロ－２－メトキシフェニル）－ｎ－｛４－［（ｓ－メチルスルホンイミドイル）メチル］ピリジン－２－イル｝ピリジン－２－アミンの使用
WO2025222187A1 (en) Compounds and uses thereof
US11185549B2 (en) Combination of a PI3K-inhibitor with an androgen receptor antagonist
EP3273963A1 (en) Use of 4-(4-fluoro-2-methoxyphenyl)-n-{3-[(s-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine for treating lymphomas
HK40060213A (en) 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer